Search Results for “” – Page 2

CRA Resident Programs

Participants gain access to focused learning resources, networking opportunities, and resident programs including the CRA Residents’ Pre-Course, National Written Rheumatology In-Training Exam (NWRITE and pediatric NWRITE), and the National Virtual OSCE. Be sure to save the following dates: Event Date […]

Apr 07, 2026

Annual Awards

Nominate a Member CRA Awards of Distinction CRA Master Awards Practice Reflection Award Abstract Awards The abstract submission system opens on September 14, 2026. Applicants must apply for abstract awards during the abstract submission process to be considered. The Abstract Awards […]

Apr 06, 2026

Canadian Rheumatology Association Position Statement on Criteria for Access to Targeted Agents for Rheumatoid Arthritis in Canada

There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting […]

Mar 30, 2026

Canadian Rheumatology Association Position Statement on Hydroxychloroquine Monitoring Guidance for Optical Coherence Tomography

The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...

Dec 01, 2025

CRA Position Statement on Quebec’s Bill 2 : Protecting Rheumatology Care and Physician Well-being

The Canadian Rheumatology Association (CRA) strongly opposes Bill 2, recently enacted by the Government of Quebec. This legislation introduces coercive measures that undermine physicians’ rights, destabilize the health care system, and threaten the quality of care for patients living with […]

Nov 05, 2025

CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors

This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]

Sep 01, 2025

Canadian Rheumatology Association Position Statement for Access to JAK Inhibitors for Children in Canada

JAK inhibitors (JAKi) are an effective treatment for several rheumatic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA)...

Mar 25, 2025